Proactive Biotech Webinar attracts strong response

The COVID-19 pandemic has placed more focus on biotech companies owing to the worldwide quest for a vaccine along with the need for increased personal hygiene. While this research and development work has thrown a strong spotlight on those companies actively involved, other biotech companies seeking new solutions to medical issues are also reporting strong interest. This interest also extended to today’s Proactive Biotech Webinar which drew a strong online presence and extensive subsequent viewing of the session. Three presenters Presenting companies were Cynata Therapeutics Ltd (ASX:CYP), Recce Pharmaceuticals Ltd (ASX:RCE) and Pharmaxis Ltd (ASX:PXS). Cynata’s managing director Dr Ross Macdonald highlighted the company's progress towards multiple clinical trials using its Cymerus™ mesenchymal stem cell (MSC) products. Recce chief executive officer James Graham summarised the company’s pathway towards developing and commercialising a new class of Synthetic Anti-infectives. Subsequent to the webinar Recce received encouraging preliminary results from an antiviral screening program at The Doherty Institute evaluating RECCE 327, a synthetic anti-infective, against SAR-CoV-2. Pharmaxis chief executive officer Gary Phillips outlined the transformational US Food & Drug Administration (FDA) agency’s approval of its cystic fibrosis treatment Bronchitol® (mannitol). Reaching this top biotech echelon is one that very few Australian companies have achieved with Phillips saying that it is a “transformational step”. The presentations can be viewed on this link: https://www.youtube.com/watch?v=NAmX5wpUv0k&ab_channel=Proactive The session starts with Cynata while the Recce presentation begins at around the 24-minute 20-second mark and the Pharmaxis presentation at the 43-minute 20-second point.